research use only
Cat.No.S7282
| Molecular Weight | 454.43 | Formula | C22H22N4O7 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1253584-84-7 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CN1CCC(CC1)NC(=O)C2=NOC(=C2)C3=C(C=C(C=C3OC4=CC=C(C=C4)[N+](=O)[O-])O)O | ||
|
In vitro |
DMSO
: 90 mg/mL
(198.05 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Targets/IC50/Ki |
HSP90
<10 nM(DC50)
|
|---|---|
| In vitro |
NMS-E973 shows a widespread antiproliferative activity with an average IC50 of 1.6 μM, and induces the degradation of client protein, such as Flt3, B-Raf, AKT, which further blocks tumour-related pathways, such as the Raf/MAPK, PI3K/AKT, and JAK/STAT pathways.
|
| Kinase Assay |
Hsp90 binding assays
|
|
For competition experiments, a protein concentration of 5 nM for Hsp90 and of 200 nM for Trap1 are mixed with 0.5 nmol/L probe (final concentrations). After incubation, the dimethyl sulfoxide (DMSO) compound solution is added to the mixture. The plate is incubated for 18 hours at room temperature and then the fluorescence polarisation signal was measured. Data are fitted with the program Dynafit version 3.28.039 or SigmaPlot (SSI) using the mathematical equation for competitive binding of 2 ligands to the receptor.
|
|
| In vivo |
NMS-E973 (10 mg/kg i.v.) shows a favourable pharmacokinetic profile with selective retention in tumour tissue and ability to cross the BBB. This compound (60 mg/kg i.v.) shows high antitumor efficacy in all the models tested, including A375 and A2780 xenografts. In addition, this chemical (10 mg/kg i.v.) together with B-Raf inhibitor PLX-4720 at 100 mg/kg produces a synergic anti-tumour effect. In a mouse model of human ovarian cancer, it produces the antitumor activity by inhibition of Hsp90.
|
References |
|
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Growth inhibition assay | Cell viability |
|
29593424 |
| Western blot | PUMA / NOXA / BID / BAD / Bak / Bmf |
|
29593424 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.